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Abstract
Background: Pirfenidone is currently approved in the EU for the treatment of mild to moderate idiopathic
pulmonary fibrosis (IPF) and offers a beneficial risk-benefit profile. However, there are several other, progressive
fibrotic lung diseases, in which conventional anti-inflammatory therapy is not sufficiently effective and antifibrotic
therapies may offer a novel treatment option.
Methods/Design: We designed a study protocol for inclusion of patients with progressive fibrotic lung disease
despite conventional anti-inflammatory therapy (EudraCT 2014–000861-32). The study population comprises
patients with collagen-vascular disease-associated lung fibrosis (CVD-LF), fibrotic non-specific interstitial pneumonia
(fNSIP), chronic hypersensitivity pneumonitis (cHP), and asbestos-related lung fibrosis (ALF). Disease progression
needs to be proven by slope calculation of at least three Forced Vital Capacity (FVC) values obtained within 6–
24 months prior to inclusion, documenting an annualized decline in percent predicted FVC of 5% (absolute) or
more despite appropriate conventional therapy. Absolute change in percent predicted FVC from baseline - analyzed
using a rank analysis of covariance (ANCOVA) model - will serve as efficacy-related primary study endpoint.
Discussion: There is an urgent unmet clinical need for effective therapies for patients with a progressive fibrotic
lung disease other than IPF. The current study protocol is unique with respect to selecting patients with different
disease entities of lung fibrosis which have, however, essential pathophysiological characteristics in common.
Moreover, by selecting patients with evidence of disease progression despite conventional therapy, the protocol
ensures that a cohort of interstitial lung disease (ILD) patients with a high unmet medical need is targeted and it
may allow a sufficiently high event rate for evaluation of treatment responses.
Trial registration: DRKS00009822 (registration date: January 13th 2016).
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Background
In the years 2011–2015, the anti-fibrotic drug pirfeni-
done (inhibitor of TGF-β, TNF α and of PDGF) and the
triple kinase inhibitor nintedanib (inhibitor of PDGF,
VEGF, and FGF) have both been approved for treatment
of Idiopathic Pulmonary Fibrosis (IPF) in the European
Union as well as in the United States. IPF is the most
frequent and aggressive diffuse parenchymal lung disease
(DPLD) in the western world. In well-designed clinical
phase III trials, both drugs have been demonstrated to
reduce the annual loss of FVC by approximately 50%
and to yield a significant reduction of all-cause mortality
after one year for pirfenidone [1–4]. Of note, there are
several DPLDs which share pathomechanistic principles,
e.g. disturbed epithelial-mesenchymal crosstalk, radio-
graphic/histological characteristics like reticulation, trac-
tion bronchiectasis and honeycombing in variable
combinations, as well as the progressive worsening and
the fatal outcome with IPF and, therefore, represent im-
portant differential diagnoses and areas of great unmet
medical need. Among these are lung fibrosis in associ-
ation to collagen/vascular diseases (CVD-LF), fibrotic
non-specific interstitial pneumonia (fNSIP), chronic
hypersensitivity pneumonitis (cHP), and asbestos-
induced lung fibrosis (ALF) [5–12]. In these entities, im-
munosuppressive therapy represents the standard clin-
ical treatment option, albeit frequently ineffective and
potentially harmful. In case of ALF, no pharmacological
treatment is available at all. Therefore, a novel treatment
option is highly needed for these most severely impaired
patients.
We hypothesized that, based on the pathophysiological
and clinical similarities between IPF and the mentioned
four types of non-IPF lung fibrosis, pirfenidone should
be a viable treatment option especially in patients in
whom conventional anti-inflammatory therapy failed.
In particular, we aim to assess whether treatment
with pirfenidone results in attenuation of the decline
in lung function and exercise capacity in these pa-
tients, similarly to what has been observed in IPF.
We will therefore conduct an exploratory efficacy and
safety study of oral pirfenidone for progressive, non-
IPF lung fibrosis (RELIEF in LUNG FIBROSIS) in
CVD-LF, fNSIP, cHP, and ALF.
Funding and ethics
This protocol is funded by the German Center for
Lung Research (Bundesministerium für Bildung und
Forschung, BMBF) and co-funded by Roche Pharma-
ceuticals. It has been approved by the ethics commit-
tee of the Ludwig-Maximilians University of Munich,
Germany. Written informed consent is obtained from
every patient enrolled.
CVD-lf
Lung fibrosis is a common feature in CVD: it can be
found in up to 80% of patients with progressive systemic
sclerosis (PSS) and in 20–50% of patients with rheumatoid
arthritis (RA) and it is not rarely observed in patients with
systemic lupus erythematosus, dermatomyositis/polymyo-
sitis and Sjögren’s syndrome [5]. Musculoskeletal pain,
weakness, fatigue, fever, joint pain or swelling, photosensi-
tivity, Raynaud’s phenomenon, pleuritis, dry eyes, or dry
mouth in the setting of lung fibrosis are important hints
for the existence of CVD-LF, but these symptoms may ap-
pear later, after lung fibrosis has already been diagnosed.
Detection of auto-antibodies such as antinuclear anti-
bodies, antibodies against extractable nuclear antigens or
of rheumatoid factor/ anti citrullinated peptide antibodies
(ACPA) may be helpful to early disclose the link between
lung fibrosis and a systemic autoimmune disease. The
most common form of pulmonary involvement is the
nonspecific interstitial pneumonia histopathologic (NSIP)
pattern, but a UIP pattern is also regularly encountered
[6]. Administration of immunosuppressant drugs may be
of help in some forms of CVD-LF (e.g. lung fibrosis asso-
ciated with Sjögren’s syndrome), but usually fails to exert
beneficial effects and disease control in the long term (e.g.
in PSS). Importantly, pulmonary involvement usually is
the key prognostic factor in these CVD and progression of
lung fibrosis is associated with worse outcome.
Idiopathic fibrotic NSIP
Originally designed as provisional entity, idiopathic NSIP
is meanwhile regarded as a separate and clearly distin-
guishable subgroup within the idiopathic interstitial
pneumonias (IIPs) [7]. NSIP seems to come along in two
peculiarities, one being the cellular form, with extensive,
general lymphoplasmacellular infiltrations of the septae,
resulting in septal thickening, but not that much fibrosis,
the other one being fibrotic NSIP, being characterized by
deposition of collagen in the septae and a more variable
extent of inflammatory reaction. Typically, however, the
alveolar structure is maintained and complex fibrosis,
such as honeycombing as observed in UIP, is absent. Al-
though the clinical picture is related to IPF (patients are
only slightly younger and more frequently female), with
coughing and exertional dyspnea representing the key
complaints, the HRCT is clearly different, showing ex-
tensive ground glass opacities in cellular NSIP and re-
ticular changes in fibrotic NSIP, usually not following a
strict centripetal gradient and being also present fre-
quently in upper lobes [8]. Patients with cellular NSIP
are usually well responding to a corticosteroid or com-
bined immunosuppressive therapy, their life-expectancy
is probably not reduced. In contrast, patients with fi-
brotic NSIP do show a much more progressive pheno-
type of the disease, with a varying degree of
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responsiveness to immunosuppressive treatment [7]. In
case such therapy fails, progressive fibrosis occurs and
will be prognostically relevant.
cHP
cHP is a type III/IV based allergic reaction, with devel-
opment of specific (so called precipitating) IgG anti-
bodies against inhaled organic antigens [9]. The
spectrum of the causative antigens is broad, covering a
multitude of antigens associated with occupational (e.g.
actinomyces thermophilus in case of the farmer lung) or
leisure (e.g. pigeon droppings and feathers in case of
pigeon breeders lung) activities. In the more acute stage,
respiratory (dyspnea, coughing) and more general (fever,
headaches) symptoms start some hours after antigen ex-
posure. During this acute episode, a primarily lympho-
cytic inflammatory reaction takes place in the lung
parenchyma, results in the formation of granuloma and
is usually associated with a CD8 dominant lymphocytic
reaction in the bronchoalveolar lavage fluid (BALF;
CD4/CD8 < 1) [9]. During this phase, the clinical picture
and the histopathological (NSIP-like pattern, lympho-
plasmacellular infiltrations, granuloma formation), radio-
graphic (nodular pattern and ground glass primarily in
upper lobes), and functional (hypoxemia, restrictive and/
or obstructive ventilation pattern) abnormalities are fully
reversible upon antigen cessation. In case of a perman-
ent and / or prolonged antigen exposure (either due to
unawareness or unavoidable contact to a known anti-
gen), the above mentioned temporal and/or spatial rela-
tionship between antigen exposure and symptoms is
lost, and there is a variably rapid and progressive decline
in lung function and exercise capacity. In this phase,
considerable percentages of neutrophils are found in
BALF, granuloma may be missing in the histopathology
and a usual interstitial pneumonia (UIP) pattern may be
observed [10]. In high-resolution computed tomography
(HRCT), fibrotic changes may mimic the classical UIP
pattern of IPF, but with peribronchiolar and upper lobe
predominance, and may result in a more complex pic-
ture, making the correct diagnosis quite difficult [11].
Also, in contrast to the primarily inflammatory triggered
early phase, an increasing number of reports suggest
that epithelial injury and apoptosis, a key feature of IPF,
play a significant role in cHP, too [12]. Immunosuppres-
sive treatment with corticosteroids is known do amelior-
ate acute episodes of HP, but has questionable effects on
chronic HP which may progress with and without per-
sistent antigen exposure [11].
Alf
Despite the prohibition of the use of asbestos in the
early ‘90s, asbestos-related lung diseases are on the peak
nowadays, illustrating the long latency observed in these
diseases. Whereas pleural asbestosis is easily diagnosed
on the basis of a corresponding patient’s history and the
typical radiographic appearance in HRCT, diagnosing
pulmonary involvement is more complex. If pleural
changes typical of asbestos-induced lung diseases are
present, any kind of interstitial lung disease should be
regarded asbestos-induced, unless a known other cause
is identified. In absence of prototypical pleural changes,
however, the association between radiographic and
histopathological findings of pulmonary fibrosis, some-
times even resembling a typical UIP pattern, and asbes-
tos can only be made on the basis of a thorough,
extensive patient history, with a focus on the profes-
sional activities [13]. Typically, the disease is progressive
in nature, with a varying rate of progression. There is no
established treatment for these patients and steroids or
immunosuppressants are typically not regarded as effect-
ive. Apart from the progressive nature of lung fibrosis,
patients with ALF or pleural asbestosis are facing the
challenge of lung cancer or mesothelioma development,
which then largely determines the prognosis. Interest-
ingly, more recent reports also indicate ongoing epithe-
lial injury in asbestos-induced lung fibrosis [14].
Efficacy and safety of pirfenidone in clinical IPF trials
Clinical safety and efficacy data on oral pirfenidone for
the treatment of patients with IPF and PF include the
following: Three published journal articles on clinical
studies evaluating oral pirfenidone for the treatment of
patients with IPF [15–17]; one controlled Phase II trial
was published in abstract form but not published as a
journal article in the medical literature: the study, PIPF-
001, was initiated by Marnac, the original Sponsor, and
completed by InterMune [18]; one study published by
the National Institutes of Health (NIH) using pirfeni-
done in patients with PF associated with Hermansky-
Pudlak Syndrome (HPS) [19]; one controlled, prospect-
ive, randomized clinical trial evaluating oral pirfenidone
in Japanese IPF patients [20]; two controlled, prospect-
ive, randomized clinical Phase III trials evaluating oral
pirfenidone in IPF patients with change in FVC as
primary endpoint (CAPACITY program, PIPF 004 and
PIPF 006) [1]; one pivotal phase III clinical trial (AS-
CEND) confirming the beneficial effect of pirfenidone
on decline of FVC, decline of 6MWD, and a significant
effect on overall mortality [2]. There is a pooled analysis
of the three randomized clinical trials [1, 2] available [3],
as well as a meta-analysis summarizing some of the clin-
ical observations made with pirfenidone in patients with
IPF [21].
On the basis of these studies, pirfenidone was autho-
rized as treatment for mild to moderate IPF in the EU in
the year 2011 and in the US after completion of the con-
firmatory ASCEND trial in 2014. In total, more than
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1650 volunteers and patients received at least one dose
of pirfenidone in clinical trials. Pirfenidone was adminis-
tered orally TID at total doses ranging from 1197 mg/d
to 3600 mg/d. The incidence of adverse events (AEs) in
clinical studies was high (approximately 80–90%) but
they were comparable in the pirfenidone and placebo
arms and in general classified as mild to moderate. In all
clinical trials, the side effect profile of pirfenidone was
similar, with gastrointestinal malaise, anorexia, weight
loss being most frequent, followed by skin rash and
photosensitivity requiring permanent use of sun
blockers. Overall, the side effects were tolerable for the
vast majority of IPF patients and only led in approxi-
mately 5% to treatment discontinuation.
Rationale for the RELIEF study
As outlined above, IPF is not the only fibrotic lung dis-
ease being characterized by a UIP pattern and by pri-
marily fibrotic (reticular) changes in HRCT. Similar
changes may be encountered in CVD-LF, cHP, and ALF.
Although distinct in terms of histopathology and HRCT,
fNSIP may act in a clinically similar manner as com-
pared to IPF. Therefore, if immunosuppressive therapy,
usually administered in CVD-LF, fNSIP, and cHP fails to
stop the progression of the disease, the life-expectancy
of patients with these forms of diffuse parenchymal lung
disease is likewise limited by the progressive nature of
the lung fibrosis. Against this background it appears
more than reasonable to speculate that pirfenidone, a
drug with a yet not completely known molecular action
profile, but profound anti-fibrotic and even anti-
inflammatory activities, may not only be effective in IPF,
but also in other, progressive forms of lung fibrosis,
where anti-inflammatory treatment modalities fail to
exert arrest of progression and/or improvement.
Aims of the study
The purpose of the RELIEF study is to assess the safety
and efficacy of treatment with pirfenidone (2403 mg/d)
compared to placebo in patients with CVD-LF, fNSIP,
cHP, and ALF.
Methods/Design
RELIEF is a prospective, randomized (1:1), placebo-
controlled clinical trial enrolling patients with progres-
sive fibrotic lung disease due to CVD-LF, fNSIP, cHP or
ALF, despite conventional anti-inflammatory therapy.
The progressive character of the underlying fibrotic lung
disease has to be objectively documented by at least
three pulmonary function tests within 6 to 24 months
prior to enrollment demonstrating an annualized per-
cent predicted FVC decline of ≥5% (absolute). The
change in lung function is determined by employing the
DZL-FVC slope calculator, a tool available on the
German Center for Lung Research DZL website (http://
www.dzl.de/index.php/de/forschung/tools/fvc-slope-
calculator).
Study endpoints
Efficacy will be assessed by the absolute change in per-
cent predicted FVC from baseline to week 48 using a
rank analysis of covariance (ANCOVA) model.
A number of key secondary endpoints were defined:
1. Time to disease worsening, defined as time to
clinical deterioration, lung fibrosis-related death,
lung transplant or respiratory hospitalization, which-
ever comes first
For the purpose of this study, clinical deterioration is
defined as follows:
1. Clinically worsening of dyspnea within 4 weeks and
2. New or worsening radiographic abnormalities on
chest x-ray or HRCT and
3. Objective worsening of PFT or gas exchange defined
by at least one of the following criteria
- Initiation of LTOT or increase of oxygen
supplementation of existing LTOT by ≥1 l/min to
maintain resting oxygen saturation (SaO2) ≥ 90%.
- Drop in FVC by >10% as compared to last
measurement
- Drop in DLCO by >15% as compared to last
measurement
- Drop in 6MWD by 20% as compared to last
measurement
2. Progression-free survival, defined as time to the first
occurrence of either of the following (as compared
to the patient’s baseline):
- ≥ 10% absolute decline in percent predicted FVC
- ≥ 15% absolute decline in percent predicted Hb-
corrected DLCO
- Death of the patient
3. Categorical assessment of relative change from
baseline to week 48 in percent predicted FVC.
4. Change from baseline to week 48 in SGRQ and EQ-
5D.
5. Change from baseline to week 48 in the percent
predicted Hb-corrected DLCO/TLCO.
6. Change from baseline to week 48 in the worst
oxygen saturation by pulse oximetry (SpO2)
measurement observed during the 6MWT.
7. Change from baseline to week 48 in distance walked
in the 6MWT.
8. Assessment of safety including overall mortality.
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Study population
Symptomatic patients at the age of 18–80 years with
a confident diagnosis (at least 9 months before
randomization) of progressive, non-IPF lung fibrosis
due to ALF, CVD-LF, cHP or fNSIP according to the
diagnostic criteria outlined in Table 1 are eligible for
this study. In addition, disease progression despite
previous or concomitant treatment (CVD-LF, chronic
HP, fNSIP) or without specific therapy (ALF) must be
documented by calculating the slope of a set of at
least three previous FVC measurements within at
least six to a maximum of 24 months before screen-
ing, showing an (eventually extrapolated) FVC decline
of at least 5 % (abs. Pred.) per year.
Additionally, the following inclusion criteria were
defined:
1. Women of childbearing capacity are required to
have a negative serum pregnancy test before
treatment and must agree to maintain highly
effective methods of contraception by practicing
abstinence or by using at least two methods of birth
control from the date of consent through the end of
the study. If abstinence is not practiced, then one of
the two methods of birth control should be an oral
contraceptive (e.g., oral contraception and a
spermicide)
2. Percent predicted FVC ≥ 40%, but <90% at the
Screening Visit (before randomization)
3. Percent predicted, hemoglobin (Hb)-corrected
carbon monoxide diffusing capacity/carbon
monoxide transfer capacity (DLCO) ≥ 25%, but
<75% at the Screening Visit
4. Distance walked ≥150 m, with O2 saturation > 83%
on ≤6 L/min of O2
5. Able to understand and sign a written informed
consent form
6. Able to understand the importance of adherence to
study treatment and the study protocol, including
the concomitant medication restrictions throughout
the study period
7. Patients being considered or on the waiting list for
lung transplantation are eligible for participation
only if their estimated waiting time is longer than
the study period. At the time these patients are
placed on the list the date and reason for this
placement and the Lung Allocation Score (LAS)
should be collected
Exclusion criteria were defined as follows
Disease-Related Exclusions:
1. Not a suitable candidate for enrollment or unlikely
to comply with the requirements of this study, in the
opinion of the investigator
2. May not survive the study period, in the opinion of
the investigator
3. Premature withdrawal from a randomized clinical
trial in the previous 2 years for any reason other
than sponsor decision or current participation in a
clinical drug trial
4. Obvious additional obstructive lung disease, as
evident from a) forced expiratory volume in the first
second (FEV1)/FVC ratio < 0.7 after administration
of a bronchodilator at Screening Visit, OR b)
bronchodilator response defined by an increase of
≥12% and an increase of ≥200 mL in the FEV1 after
bronchodilator use compared to the value seen
before bronchodilator at the Screening Visit, OR c)
residual volume (RV) > 140% of predicted (before
administration of bronchodilator)
5. Other explanation for interstitial lung disease,
including but not limited to radiation, sarcoidosis,
bronchiolitis obliterans organizing pneumonia,
Table 1 Diagnostic Criteria of RELIEF Patient Categories (all to
be fulfilled within each category)
Lung fibrosis associated with collagen / vascular diseases
• Diagnosis of progressive systemic sclerosis (PSS), rheumatoid
arthritis (RA), Sjörgen’s syndrome, polymyositis/dermatomyositis on
the basis of extrapulmonary symptoms and corresponding proof of
auto-antibodies
• Reticular changes in HRCT and restrictive lung function pattern
• Absence of an alternative explanation for fibrotic lung disease
Fibrotic NSIP
• Histological diagnosis of a fibrotic NSIP pattern by open lung biopsy
or cryobiopsy
• HRCT consistent with fibrotic NSIP
• Restrictive lung function pattern
• Absence of an alternative explanation for fibrotic lung disease,
especially no clinical suspicion of CVD
Chronic Hypersensitivity Pneumonitis
• Previous or current respiratory symptoms (dyspnea, coughing) with
a temporal or spatial relation to a causative antigen exposure
• Proof of precipitating antibody and/or lymphocytic alveolitis (>30%)
• HRCT consistent with chronic HP
• Restrictive lung function pattern
• Absence of an alternative explanation for fibrotic lung disease
Asbestos-induced lung fibrosis
• Existence of asbestos-specific pleural changes in HRCT (pleural
plaques)
• Reticular changes in HRCT and restrictive lung function pattern
• History of asbestos exposure
• Absence of an alternative explanation for fibrotic lung disease
• Absence of extensive pleural plaques and/or effusion
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human immunodeficiency virus (HIV), viral hepatitis
and cancer
6. Clinical evidence of active infection, including but
not limited to bronchitis, pneumonia, sinusitis,
urinary tract infection, or cellulitis
7. In the clinical opinion of the investigator, the patient
is expected to need and be eligible for a lung
transplant within 52 weeks after randomization
8. Unable to undergo pulmonary function testing
Medical Exclusions:
9. Any history of malignancy likely to result in death or
significant disability or likely to require significant
medical or surgical intervention within the next
2 years. This does not include minor surgical
procedures for localized carcinoma (e.g., basal cell
carcinoma).
10.Any condition other than lung fibrosis which, in the
opinion of the investigator, is likely to result in the
death of the patient within the next 2 years.
11.History of advanced cirrhosis or clinically significant
liver disease.
12.History of unstable or deteriorating cardiac or
pulmonary disease (other than IPF) within the
previous 6 months, including but not limited to the
following:
- Myocardial infarction, unstable angina pectoris,
coronary artery bypass surgery, or coronary
angioplasty
- Congestive heart failure requiring hospitalization
- Uncontrolled arrhythmias
- Asthma or chronic bronchitis requiring
hospitalization in the last 6 months
13.Any condition, which, in the opinion of the
investigator, might be significantly exacerbated by
the known side effects associated with the
administration of pirfenidone.
14.Poorly controlled diabetes (defined by glycosylated
hemoglobin [HbA1C] >10%).
15.Pregnancy or lactation.
16.History of alcohol or substance abuse in the past
2 years.
17.History of any condition or habit associated with
altered consciousness and a risk of aspiration in the
past 2 years.
18.Family or personal history of long QT Syndrome.
19.Treatment with either one of the following
medications: fluvoxamine (any time), any
investigational drug, PH-specific mediation unless
initiated >6 months ago and kept stable thereafter
and throughout study period.
20.Severe pulmonary hypertension with PVR values
>900 dyn.
21.Smoking.
Laboratory Exclusions:
22.Any of the following liver function test criteria
above specified limits: Total bilirubin >2.5 upper
limit of normal (ULN); aspartate or alanine
aminotransferase (AST/SGOT or ALT/SGPT) >2.5
ULN; alkaline phosphatase >2.5 ULN
Concomitant Therapy Exclusions:
23.Severe liver failure.
24.Prior use of pirfenidone.
25.Hypersensitivity/allergy against pirfenidone or any
component of the investigational medicinal product
(IMP).
26.History of angioedema in relation to prior use of
pirfenidone.
27.Severe renal failure defined as GFR < 30 ml/min
and/or need for dialysis.
28.Concomitant therapy with potential interaction to
study drug according to SmPC.
29.Patients are excluded if more than 15 mg
prednisolon equivalent are applied per day or if a
pre-existent steroid and/or immunosuppressant
therapy has been modified within the last 3 months
and/or if such therapy would be needed to be chan-
ged during the study period. In that case, dosing has
to be adjusted and patient must be re-checked for
eligibility 3 months after the last dose adjustment.
Concomitant therapy
Drugs that are considered necessary for the patient’s
welfare may be given at the discretion of the investigator
with respect to the potential interactions according to
Summary of Product Characteristics (SMPC). However,
careful monitoring for new symptoms by the patient is
vital in this instance. Information on concomitant medi-
cations will be collected until the final Follow-Up Visit.
For patients who withdraw from study, data on con-
comitant medications will be collected until the later of
the following two time points:
1. Time of consent withdrawal.
2. 28 days after last dose of study treatment.
With the exception of clinical deterioration (for defin-
ition see study endpoints) due to disease.
progression therapies listed below are not permitted
during the study:
- Any investigational therapies (i.e., agents that are not
approved by local regulatory agencies, including N-
acetyl-cysteine (NAC) at a dose >600 mg/d)
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- Any interferon therapy, including IFN-γ 1b
- Any cytokine modulators (including but not limited
to etanercept and infliximab)
- Any other therapy that has been investigated or used
off-label as a treatment for lung fibrosis including but
not limited to d-penicillamine, colchicine, bosentan,
imatinib mesylate, and cyclosporine A, rituximab. If
patients receive any of these excluded therapies while on
study, it will be recorded in the e-CRF and will be
considered as a protocol violation.
In case of a clinical deterioration due to disease pro-
gression, pulse-dose steroids may be used for a period of
up to 14 days, as well as any of the above mentioned
and other “rescue” therapies such as plasma separation.
This will be entirely left to the discretion of the investi-
gator and have to be documented in the e-CRF.
Statistical considerations
Hypotheses
Hierarchical testing will be applied in the final analysis
to test the treatment effect in different groups with re-
gard to diagnosis (see Table 1 for diagnostic categories).
The hypothesis H0: “no difference in absolute change in
percent predicted FVC from baseline to week 48 be-
tween the pirfenidone and placebo group” will be tested
against the alternative H1: “difference in absolute change
in percent predicted FVC from baseline to week 48
between the pirfenidone and placebo group”. The order
of hypothesis testing is defined as follows:
1. H0 against H1 in the overall group
2. H0 against H1 in the group in which the diagnosis
group with the smallest number of patients is
excluded
3. H0 against H1 in the group in which the diagnosis
group with the second smallest number of patients
is excluded
4. H0 against H1 in the diagnosis group which has the
highest number of patients
5. H0 against H1 in the diagnosis group which has the
second highest number of patients
6. H0 against H1 in the diagnosis group which has the
third highest number of patients
7. H0 against H1 in the diagnosis group which has the
smallest number of patients
Hypotheses are tested consecutively until the p-value of a
hypothesis exceeds the 5% significance level, thereby con-
trolling the familywise error rate (FWER) at the 5% level.
Analysis population
The intention-to-treat (ITT) population is defined as all
randomized patients. All analyses of outcome parame-
ters will be based on the intention-to-treat population.
The per protocol (PP) population comprises all pa-
tients who had no major protocol deviation with respect
to the primary endpoint. The analysis of the primary
endpoint will also be provided for the per protocol
population.
The as treated population is defined as all included pa-
tients who received at least one dose of the investigational
medicinal product (IMP). Analysis of safety will be based
on the as treated population, i. e. patients will be analyzed
according to the treatment they actually received.
Sample size
The sample size and power calculations are based on the
analysis of the primary efficacy endpoint in the overall
group: absolute change in percent predicted FVC from
baseline to week 48. It is assumed that the primary effi-
cacy endpoint is not normally distributed and that its
probability distributions are identical in both treatment
populations, except for location. Assuming furthermore
a similar treatment effect in all clinical diagnosis groups
(see Table 1 for diagnostic categories), the two-sample
Mann-Whitney U Test for independent samples is used
to test for a difference in median. For a group sequential
design according to O’Brien/Fleming with one interim
analysis, a two-sided significance level of 5% and a
power of 80%, 187 patients per arm are needed to detect
an effect size of 0.3 between the two treatment groups
across all indications. The magnitude of the effect size
was based on the observed rank effects (i.e. effect in a
non-parametric analysis) of pirfenidone versus placebo
in the CAPACITY study at 1 year (48 weeks) corre-
sponding to an effect size of 30% after scaling back. In
the pooled CAPACITY studies the effect size was around
40%. The conservative choice of the effect size allows for
a dropout rate like in CAPACITY [1].
Sample size calculation in ADDPLAN 6.0 is only avail-
able for group sequential designs based on t tests.
Therefore, the results were multiplied by the factor π/3
for nonparametric adjustment as proposed by Al-
Sunduqchi and Guenther (1990) (Determining the Ap-
propriate Sample Size for Inferences Based on the Wil-
coxon Statistics. Ph.D. dissertation under the direction
of William C. Guenther, Dept. of Statistics, University of
Wyoming, Laramie, Wyoming) and implemented in
PASS 2008 [22].
Interim analysis
There is one planned interim analysis for efficacy. An in-
terim analysis will be performed after completion of
treatment in 224 patients which is expected to occur at
about two and a half years after start of accrual. The sig-
nificance level in the interim analysis is 0.0101 and the
power for a positive result in the interim analysis is
about 35% if the true effect size equals 0.3.
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Primary endpoint
The primary efficacy analysis will be to investigate the
treatment effect on the absolute change in percent pre-
dicted FVC from baseline in the pirfenidone and placebo
group with regard to each hypothesis tested. As the pri-
mary efficacy endpoint is assumed to be not normally
distributed, data will be analyzed using a rank analysis of
covariance (ANCOVA) model with a classification effect
for treatment and diagnostic category and baseline FVC
as a covariate. The null hypothesis is tested against the
alternative hypothesis at a two-sided significance level of
5%. The treatment effect will be tested using the
Cochran-Mantel-Haenszel mean score statistic, median
treatment differences will be estimated according to
Hodges-Lehmann. The applied methods are based on a
location-shift model assuming that the metric distribu-
tions of the absolute change in percent predicted FVC
are the same, except for location. Furthermore, the pri-
mary efficacy endpoint will be analyzed by factorial
ANCOVA with a classification effect for treatment and
diagnostic category (with and without an interaction
term for treatment and diagnostic category) and baseline
FVC as a covariate.
Handling of missing values in rank ANCOVA
Patients with missing values due to death will be
assigned the worst ranks according to the time from
randomization until death where the shortest time until
death corresponds to the worst rank.
A missing value at Visit X in Patient A who is alive at
that time will be imputed as follows. For patients with-
out any missing values from baseline up to Visit X the
sum of squared differences (SSD) between each patient
and Patient A is calculated across all values from base-
line up to one visit before Visit X. The three patients
with the smallest SSD will be taken into account for im-
puting the missing value for Patient A at Visit X by tak-
ing the average value of the three patients at that visit.
Secondary endpoints
Secondary outcomes will be analyzed by using appropri-
ate statistical methods, e.g. Kaplan-Meier estimates and
rank ANCOVA. Additional analyses will be described in
detail in a statistical analysis plan (SAP) before data base
closure.
Safety endpoints
Safety data will be summarized by using descriptive stat-
istical methods.
Discussion
The study is unique for several reasons. First, it allows to
enroll patients with different forms of interstitial lung dis-
ease. Second, a common progressive fibrotic phenotype of
ILD is defined by radiomorphology on high-resolution
thin section computed tomography and, more import-
antly, by at least three spirometric measurements within 6
to 24 months, which show an annual decline in percent
predicted FVC of at least 5% (absolute). Third, study
medication (i.e. pirfenidone or placebo) is used on top of
existing anti-inflammatory medication, which has to be
stable for at least three months. If progressive fibrosis is
the common pathophysiological pathway in these diseases,
there is good chance that antifibrotic effects of pirfenidone
ameliorate disease progression in this group of diseases.
Trial status
Initiation of the participating sixteen centers throughout
Germany started in April 2016. In March 2017 four add-
itional centers were activated and by May 3rd 2017 a
total of 74 patients have been randomized.
Key messages
Fibrotic interstitial lung disease other than IPF com-
prises a variety of different diseases in which current
conventional anti-inflammatory therapies are frequently
ineffective.
There is an urgent unmet clinical need for effective
therapies for interstitial lung diseases with a progressive
fibrotic phenotype other than IPF.
Pirfenidone has shown a favorable benefit-risk profile
in IPF and therefore appears highly likely to be effective
also in other fibrotic lung diseases.
The RELIEF protocol allows enrollment of patients
with four selected disease entities and evidence of dis-
ease progression despite anti-inflammatory therapy as a
Phase II study for the use of antifibrotic drugs in these
diseases.
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